Application No.: 10/502,049

Attorney Docket No.: STAH3008/REF/LES

## LISTING AND AMENDMENT OF THE CLAIMS

1-31. (Canceled).

32. (Currently Amended) A method for treating an infection in a patient, comprising orally administering to a patient in need thereof a therapeutically effective amount of <u>a food</u> and/or dietetic composition comprising one or more sialyzed carbohydrates <u>selected from the group consisting of disialyl-lacto-N-tetraose (DS-LNT)</u>, disialyl-lacto-N-neo-tetraose (DS-LNT), glycomacropeptide (GMP), ganglioside G<sub>D1a</sub>, ganglioside G<sub>T1b</sub> and ganglioside G<sub>T1c</sub> of formula I:

wherein:

Sia means a sialic acid or an O acetyl sialic acid derivative in an α 2–3 bond, Gal means a galactose monosaccharide unit,

HexNac means an N-acetylated galactosamine-monosaccharide unit or glucosamine-monosaccharide unit (GalNAc or GlcNAc),

Hex means a galactose monosaccharide unit or glucose monosaccharide unit (Gal or Gle),

C represents HexNac or Hex or is absent,

n represents 1 to 50,

wherein X is a first sialic acid or an O-acetyl sialic acid derivative thereof, optionally having a second sialic acid or an O-acetyl-sialic acid derivative bound to the first sialic acid or O-acetyl sialic acid derivative in an α 2-3 bond, a phosphate group, a sulphate group, carboxyl group, or a monosaccharide having a phosphate group, sulphate group or carboxyl group,


wherein only one of the residues X is present,

V is a) OH when a represents 1, b) a carbohydrate residue or c) a connecting point on a carrier T, with the proviso that when V represents b) a carbohydrate residue being a monosaccharide residue, an oligosaccharide residue or a polysaccharide residue or c) a carrier T,

Application No.: 10/502,049

Attorney Docket No.: STAH3008/REF/LES

n means the number of the carbohydrate units of formula II that are each directly bound to this b) carbohydrate residue or c) carrier, and formula II is as follows:



and

—— wherein the sialyzed carbohydrate are in a form so that sia α 2–3 residues of said sialyzed carbohydrates bind to pathogens; and

said sialyzed carbohydrates are incorporated in said food and/or dietetic composition.

33-35. (Canceled).

- 36. (Currently Amended) The method according to claim 32, wherein the earbohydrate or carbohydrates of formula I are administered in an amount of 1 mg per kg of body weight of said patient.
- 37. (Previously Presented) The method according to claim 32, wherein the patient has an infection of the gastrointestinal tract, blood system, respiratory passage, urogenital tract, or nasopharynx.

39-40. (Canceled).

- 41. (Previously Presented) The method of claim 32, wherein the patient has an infection of the gastrointestinal tract and the patient is human.
- 42. (Currently Amended) A food <u>and/or</u> a dietitic composition <del>composition in a form for oral administration-comprising aone or more</del> sialyzed <del>carbohydrate</del> <u>carbohydrates selected from</u> the group consisting of disialyl-lacto-N-tetraose (DS-LNT), disialyl-lacto-N-neo-tetraose (DS-

Application No.: 10/502,049 Attorney Docket No.: STAH3008/REF/LES

LNnT), glycomacropeptide (GMP), ganglioside G<sub>D1a</sub>, ganglioside G<sub>T1b</sub> and ganglioside G<sub>T1c</sub> of formula I:

wherein:

Sia means a sialic-acid or an O acetyl sialic acid derivative in an α 2-3 bond, Gal-means a galactose-monosaccharide unit,

HexNac means an N-acetylated galactosamine-monosaccharide unit or glueosamine-monosaccharide unit (GalNAc or GleNAc),

Hex means a galactose monosaccharide unit or glucose-monosaccharide unit (Gal or Gle),

C represents HexNac or Hex or is absent,

n represents 1 to 50,

wherein X is a first sialic acid or an O acetyl sialic acid derivative thereof, optionally having a second sialic acid or an O acetyl sialic acid derivative bound to the first sialic acid or O acetyl sialic acid derivative in an α 2-3 bond, a phosphate group, a sulphate group, carboxyl group, or a monosaccharide having a phosphate group, sulphate group or carboxyl group,

- wherein only one of the residues X is present,

V is a) OH when n represents 1, b) a carbohydrate residue or c) a connecting point on a earrier T, with the proviso that when V represents b) a carbohydrate residue being a monosaccharide residue, an oligosaccharide residue or a polysaccharide residue or c) a carrier T, n means the number of the carbohydrate units of formula II that are each directly bound to this b) earbohydrate residue or c) carrier, and formula II is as follows:

Application No.: 10/502,049

Attorney Docket No.: STAH3008/REF/LES

and

wherein the sialyzed carbohydrate are in a form so that sia α 2-3 residues of said sialyzed carbohydrates bind to pathogens; and

said sialyzed carbohydrates are incorporated in a food and/or dietetic composition.

43. (Previously Presented) The composition according to claim 42, further comprising an auxiliary agent, diluent, moisturizing agent, thickening agent, flavoring agent, sweetening agent, or carrier.

44-49. (Canceled).

- 50. (Currently Amended) The composition according to claim 42, wherein the composition is in a form selected from the group consisting of a beverage, baby formula, food supplement, infant formula, milk product, chocolate, cheese, sausage, meat product, anabolic food, and probe tube foodfood administered via a feeding tube.
- 51. (Previously Presented) A method for treating a bacterial infection in a patient, comprising orally administering an effective amount of the composition according to claim 42 to said patient.
  - 52. (Canceled).
- 53. (Previously Presented) The method according to claim 32, wherein the patient is a pregnant women, an infant, debilitated person, or an elderly person.
- 54. (New) The method according to claim 32, wherein said sialyzed carbohydrates are connected to a carrier.
- 55. (New) The method according to claim 54, wherein said carrier is selected from the group consisting of polymers, carbohydrates, glycolipids and gangliosides.

Application No.: 10/502,049 Attorney Docket No.: STAH3008/REF/LES

56. (New) The method according to claim 55, wherein said carrier is a biopolymer selected from the group consisting of peptides and proteins.

- 57. (New) The composition according to claim 42, wherein said sialyzed carbohydrates are connected to a carrier.
- 58. (New) The compostion according to claim 57, wherein said carrier is selected from the group consisting of polymers, carbohydrates, glycolipids and gangliosides.
- 59. (New) The compostion according to claim 58, wherein said carrier is a biopolymer selected from the group consisting of peptides and proteins.
- 60. (New) The method according to claim 32, wherein said food and/or dietetic composition is not human milk.
- 61. (New) The composition according to claim 42, wherein said food and/or dietetic composition is not human milk.